What are the next steps for a patient with adenomyosis, fibroids, and endometriosis, who continues to experience heavy bleeding despite initial intervention, has undergone hysteroscopy with benign histopathology results, and requires further management to control symptoms?

Management of Refractory Heavy Menstrual Bleeding in Adenomyosis with Fibroids and Endometriosis

For a patient with adenomyosis, fibroids, and endometriosis experiencing persistent heavy bleeding despite hysteroscopy with benign histopathology, medical management with either a levonorgestrel-releasing IUD or uterine artery embolization should be the next step, with hysterectomy reserved as definitive therapy if these fail. 1, 2

Immediate Next Steps: Medical Management

First-Line Medical Options

The levonorgestrel-releasing intrauterine system (LNG-IUS) is the single most effective medical therapy for heavy menstrual bleeding in adenomyosis, reducing menstrual blood loss more effectively than any other medical option. 3 This is particularly important given your concurrent adenomyosis, which notoriously causes treatment failure with endometrial ablation. 1

If the LNG-IUS is contraindicated or declined:

• Add tranexamic acid to any current hormonal therapy as the first escalation step, as this is the most common approach (53% of clinicians use this strategy). 4 Tranexamic acid provides excellent nonhormonal bleeding control and can be combined with hormonal contraceptives. 2, 5

• Oral GnRH antagonists with mandatory hormone add-back therapy reduce fibroid volume by 18-30% and effectively control bleeding in adenomyosis. 2, 6 The add-back therapy is essential to prevent bone density loss and hypoestrogenic symptoms. 6

Critical Pitfall to Avoid

Do not pursue endometrial ablation in your case. Treatment failure rates are significantly elevated when adenomyosis is present, making this a poor choice despite the benign histopathology. 1

Minimally Invasive Interventional Therapy

Uterine Artery Embolization (UAE)

For concurrent adenomyosis with fibroids, UAE is specifically recommended as a preferred initial approach alongside medical management. 1, 2 This is particularly relevant to your case because:

• UAE provides 94% short-term and 85% long-term symptom improvement with quality of life benefits lasting up to 7 years. 7

• UAE achieves superior fibroid diameter reduction (53%) and has lower reintervention rates (13% at follow-up) compared to MR-guided focused ultrasound (30% reintervention rate). 7

• UAE is equally effective as myomectomy for reducing heavy menstrual bleeding at 4 years, with lower blood transfusion risk and shorter hospital stays. 1

• The 10-year data shows secondary hysterectomy rates of 35%, meaning 65% of patients avoid hysterectomy long-term. 1

Why Not MRgFUS?

MRgFUS has significantly higher reintervention rates and is less durable for multiple pathologies like yours. 2, 7 Given your complex presentation with adenomyosis, fibroids, and endometriosis, UAE offers more comprehensive treatment.

Definitive Surgical Management

Hysterectomy as Next Step

If medical management and UAE fail to control bleeding, hysterectomy provides definitive resolution with patient satisfaction rates up to 90%. 2, 6 This is particularly appropriate because:

• Hysterectomy eliminates risk of recurrence and simultaneously treats all three conditions (adenomyosis, fibroids, and endometriosis). 1

• For postmenopausal patients or those with completed childbearing, hysterectomy is the recommended next step after negative endometrial evaluation (which you have). 1

• The least invasive route should be chosen (vaginal or laparoscopic preferred over abdominal) to minimize complications, hospital stay, and recovery time. 1

Important Counseling Points

• Even with ovarian conservation, hysterectomy carries elevated cardiovascular and mood disorder risks, with some studies showing increased mortality when performed at young age. 1

• Short-term complications include venous thromboembolism, organ injury, and bleeding requiring transfusion. 1

• Long-term effects include increased cardiovascular disease risk, osteoporosis, bone fractures, and dementia. 1

Treatment Algorithm Summary

1. Immediate step: Trial LNG-IUS (most effective medical option for adenomyosis) 3

2. If LNG-IUS fails or contraindicated: Add tranexamic acid to current hormonal therapy OR initiate oral GnRH antagonist with add-back therapy 4, 2

3. If medical management inadequate: Proceed to UAE (specifically recommended for adenomyosis with fibroids) 1, 2

4. If UAE fails or patient prefers definitive treatment: Hysterectomy via least invasive route 1, 2

Special Consideration for Your Endometriosis

While dienogest is effective for endometriosis pain, patients with adenomyosis have 9-fold increased odds of moderate-to-severe bleeding with dienogest (OR 9.00, P=0.049). 8 If currently on dienogest, this may be contributing to your persistent bleeding and should be reconsidered.